# Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease

> **NCT07452822** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Topcel-KH Pharmaceutical Co., Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Arteriovenous Fistula Stenosis

## Interventions

- **BIOLOGICAL:** Human umbilical cord mesenchymal stem cells injection
- **OTHER:** saline solution

## Key facts

- **NCT ID:** NCT07452822
- **Lead sponsor:** Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-20
- **Primary completion:** 2027-03-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07452822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07452822, "Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07452822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*